Close
Show

2022 Cold Chain Predictions: Creating a new Normal

REGENXBIO Announces Orphan Drug Designation Granted to RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy
20989